RYTM
Rhythm Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +5.3% ·
share flow +5.1% ·
net new positions 0.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 112 | +7 | 44.38M | $4.90B | +14 | −8 |
| Q1 2026 | 109 | +6 | 41.83M | $3.64B | +11 | −6 |
| Q4 2025 | 102 | 0 | 43.14M | $4.62B | +3 | −2 |
| Q3 2025 | 20 | +1 | 28.88M | $2.92B | +2 | −2 |
| Q2 2025 | 17 | 0 | 22.96M | $1.45B | +1 | −1 |
| Q1 2025 | 14 | +2 | 11.52M | $610.22M | +2 | — |
| Q4 2024 | 12 | 0 | 11.40M | $638.39M | — | — |
| Q3 2024 | 11 | +3 | 9.71M | $508.75M | +3 | — |
| Q2 2024 | 8 | — | 9.56M | $392.54M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 6.30M | +0.6% | $636.46M | 0.0% | ▲ Add | 2 | SEC ↗ ×16 |
| 2 | The Vanguard Group ✦ (passive) | 5.00M | +39.2% | $504.59M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 3 | PRIMECAP Management ✦ | 4.26M | -12.6% | $430.51M | 0.3% | ▼ Trim | 6 | SEC ↗ |
| 4 | JPMorgan Chase ✦ | 2.38M | — | $239.97M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 5 | Fidelity (FMR) ✦ | 2.15M | +9.8% | $216.64M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 6 | State Street Global Advisors ✦ (passive) | 2.03M | +6.3% | $204.87M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Goldman Sachs Group ✦ | 1.89M | — | $191.24M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 8 | T. Rowe Price ✦ | 1.40M | +4.4% | $141.38M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | Geode Capital Management ✦ (passive) | 1.36M | +3.9% | $137.65M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 10 | Renaissance Technologies ✦ | 546.59K | +73.6% | $55.20M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 11 | Adage Capital Partners ✦ | 544.00K | +59.5% | $54.94M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 12 | Morgan Stanley ✦ | 465.19K | — | $46.98M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 13 | Marshall Wace ✦ | 171.83K | -54.3% | $17.35M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 14 | Millennium Management ✦ | 133.16K | -32.8% | $13.45M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 132.63K | New | $13.39M | 0.0% | New | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 79.78K | +62.7% | $8.06M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 17 | Wellington Management ✦ | 24.48K | +9.2% | $2.47M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 18 | Arrowstreet Capital ✦ | 6.31K | New | $636,944 | 0.0% | New | 1 | SEC ↗ |
| 19 | Gotham Asset Management ✦ | 4.86K | +0.1% | $490,306 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 20 | D. E. Shaw & Co. ✦ | 3.58K | -85.2% | $362,049 | 0.0% | ▼ Trim | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Citadel Advisors | $13.39M | 0.0% |
| Arrowstreet Capital | $636,944 | 0.0% |
Exited
| Norges Bank | $13.10M | was 0.0% |
| Point72 Asset Management | $10.79M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 284 holders, 72.02M shares, $6.12B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 1.82K sh · $189,965
Officer, Director · 8.70K sh · $899,634
Officer, Director · 30.75K sh · $3.15M
Officer, Director · 6.44K sh · $655,145
Officer, Director · 2.30K sh · $241,937
Officer · 11.51K sh · $1.21M
Officer · 23.07K sh · $2.41M
Officer · 28.19K sh · $2.99M
Officer · 2.01K sh · $233,031
Officer · 1.56K sh · $182,170
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology